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Skip this step  
when checking lipid levels
Although most guidelines recommend that patients 
fast before lipid testing, this study found no difference 
between fasting and nonfasting testing for predicting 
mortality.
PRACTICE CHANGER
Stop requiring your patients to fast before 
undergoing lipid testing. Nonfasting total 
cholesterol (TC), high-density lipoprotein 
cholesterol (HDL), and low-density lipo-
protein cholesterol (LDL) levels are equally 
predictive of cardiovascular mortality and 
all-cause mortality.1
StRENGtH oF RECoMMENDAtioN
B: Based on a large, cross-sectional cohort 
study of adults followed for a mean of 14 years 
with patient-oriented outcomes. 
Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfast-
ing low-density lipoprotein cholesterol levels on long-term mortality: 
insight from the National Health and Nutrition Examination Survey III 
(NHANES-III). Circulation. 2014;130:546-553.
ILLUSTRATIVE CASE
A 57-year-old man with diabetes refuses to 
fast before coming to the clinic for lipid test-
ing because he’s afraid he’ll become hypo-
glycemic. You have not been able to obtain a 
lipid panel on him for more than a year and 
you want to determine his lDl level. Will a 
nonfasting lipid panel be useful?
Approximately 71 million US adults have high LDL.2 The 2013 Ameri-can College of Cardiology/American 
Heart Association guidelines recommend 
fasting cholesterol checks for all adults ages 
21 and older for primary prevention of cardio-
vascular disease.3 The US Preventive Services 
Task Force (USPSTF) has long recommended 
screening cholesterol in adults to prevent 
atherosclerotic vascular disease. 
In 2008, the USPSTF recommended lipid 
screening for all men ages 35 years and older, 
for all men ages 20 to 35 years who are at in-
creased risk for coronary heart disease, and 
for all women ages 20 years and older who are 
at increased risk for coronary heart disease.4 
The USPSTF recommends TC and HDL as the 
preferred screening tests and states that these 
tests can be performed on fasting or nonfast-
ing samples, but if LDL is added, a fasting 
sample is recommended.4 Other national 
and international guidelines on cholesterol 
management also recommend a fasting lipid 
panel to stratify patients’ risk and determine 
treatment options.5-7 
LDL usually is reported as a calculated val-
ue using the Friedewald equation (LDL equals 
TC minus HDL minus [triglycerides divided by 
5]).8 This calculation is not accurate for patients 
with triglyceride levels >400 mg/dL, which has 
prompted most authorities to recommend a 
fasting sample. That’s because while TC and 
HDL are not affected by food (and LDL may 
vary by only 10% or less), triglycerides can fluc-
tuate by 20% to 30%, which would influence 
the calculation of a nonfasting LDL.9,10 LDL can 
be measured directly, but the process is gener-
ally expensive and not commonly used.11
The Centers for Disease Control and Pre-
vention (CDC) estimates that over 20% of US 
adults (more than 48 million people) have 
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not had a screening lipid panel in the previ-
ous 5 years.12 One barrier to screening is that 
both physicians and patients often believe 
that a fasting specimen is required. Yet fast-
ing specimens are difficult to obtain because 
they often require a separate visit to the clin-
ic, which can result in lost time from work 
and additional transportation costs.
STUDY SUMMARY
there’s no difference between fasting 
and nonfasting LDL
Doran et al1 used data from the NHANES-
III survey to compare the prognostic value 
of fasting vs nonfasting LDL for all-cause 
mortality and cardiovascular mortality. 
NHANES-III is a nationally representative 
cross-sectional survey that was performed 
from 1988 to 1994.13 Doran et al1 included 
16,161 US adults ages 18 years and older for 
whom data on fasting time were available. 
Participants for whom LDL calculations were 
not possible due to missing HDL, TC, or tri-
glyceride levels were excluded. Those with 
triglycerides ≥400 mg/dL were excluded from 
the primary analysis. 
Participants were stratified based on 
fasting status (≥8 hours or <8 hours) and 
followed for a mean of 14 (± .22) years. To 
control for possible cofounders, researchers 
used propensity score matching to identify 
4299 pairs of fasting and nonfasting individu-
als with similar cardiovascular risk factors, 
including race, smoking history, prior car-
diovascular disease, cholesterol medication 
use, diabetes, elevated TC, low HDL, hyper-
tension, enlarged waist circumference, and 
low socioeconomic status. After matching, 
the baseline characteristics of the fasting and 
nonfasting groups were similar. 
The primary outcome was all-cause mor-
tality, and the secondary outcome was car-
diovascular mortality. The prognostic value of 
fasting and nonfasting LDL for these outcomes 
was evaluated as the area under the receiver 
operator curve (ROC) using the Hosmer-
Lemeshow C-statistic.14 (In this case, similar 
C-statistics indicate that the tests have simi-
lar prognostic values.*) Kaplan-Meier curves 
were used to assess survival. The association 
of LDL with mortality, after adjustment of 
potential confounders, was evaluated using 
Cox proportional hazard models. The groups 
were divided into tertiles based on LDL levels 
(<100 mg/dL, 100-130 mg/dL, and >130 mg/dL). 
As expected, compared to individuals 
in the first LDL tertile (<100 mg/dL), those 
with a higher LDL had an increased risk of 
all-cause mortality (hazard ratio [HR]=1.61; 
95% confidence interval [CI], 1.25-2.08 [sec-
ond tertile] and HR=2.10;  95% CI, 1.70-2.61 
[third tertile]). The prognostic value of fasting 
vs nonfasting status for predicting all-cause 
mortality was similar, as suggested by the C-
statistics (0.59 [95% CI, 0.56-0.61] vs 0.58 [95% 
CI, 0.56-0.60]; P=.73). 
The risk of cardiovascular mortality also 
increased with increasing LDL tertiles. As 
was the case with all-cause mortality, the 
prognostic value of fasting vs nonfasting sta-
tus was similar for predicting cardiovascular 
mortality as observed by similar C-statistics 
(0.64 [95% CI, 0.62-0.66] vs 0.63 [95% CI, 0.60-
0.65]; P=.49). In addition, fasting vs nonfast-
ing C-statistics were similar for both diabetic 
and non-diabetic patients.
WHAT’S NEW?
Results suggest fasting  
may no longer be necessary
While obtaining a fasting lipid panel is rec-
ommended by multiple guidelines and has 
become traditional practice, the need for fast-
ing originated primarily out of concern for the 
effect of postprandial triglycerides on calculat-
ing LDL. This is the first study that compared 
the prognostic value of fasting and nonfasting 
LDL values for predicting mortality; it demon-
strated that they are essentially the same.
CAVEATS
Fasting and nonfasting measurements  
were taken from different patients 
The fasting and nonfasting lipids were not 
collected from the same individuals. How-
ever, to decrease confounding, Doran et al1 
factored in multiple cardiovascular risk fac-
tors as covariables. 
Another caveat is that individuals with 
the prognostic 
value of fasting 
vs nonfasting 
status for  
predicting  
all-cause  
mortality was 
similar.
* The C-statistic is the probability that predicting the outcome is better than chance and is used to compare the goodness of fit of logistic regression 
models. Values for this measure range from 0.5 to 1.0. A value of 0.5 indicates that the model is no better than chance at making a prediction of 
membership in a group and a value of 1.0 indicates that the model perfectly identifies those within a group and those not.
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the only  
challenge: it may 
be difficult for 
physicians to 
change a  
longstanding 
practice of  
checking  
fasting lipid  
profiles.
triglyceride levels >400 mg/dL were exclud-
ed. However, investigators ran a sensitivity 
analysis that included individuals with tri-
glycerides >400 mg/dL and found no signifi-
cant difference in C-statistics between the 
fasting and nonfasting groups. 
CHALLENGES TO IMPLEMENTATION
Dropping the requirement to fast 
goes against established practice
It may be difficult for physicians to change 
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